The treatment paradigm for lung cancer has changed in the last years: Nowadays, in particular for patients without targetable genetic alterations, checkpoint inhibitor therapy combined with platinum‐based chemotherapy is the standard of care in first‐line treatment in patients with metastatic NSCLC independently of PD‐L1 expression status [6, 7, 8]. This evidence concerns the gene CD274 and lung cancer.